OTCMKTS:NWBO Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis → Reclusive millionaire’s final warning about America (From Weiss Ratings) (Ad) Free NWBO Stock Alerts $0.50 +0.07 (+16.37%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$0.43▼$0.5050-Day Range$0.42▼$0.5452-Week Range$0.40▼$1.09Volume3.76 million shsAverage Volume1.48 million shsMarket Capitalization$610.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Northwest Biotherapeutics alerts: Email Address Ad Weiss RatingsReclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.Click here to learn how to prepare before it's too late. About Northwest Biotherapeutics Stock (OTCMKTS:NWBO)Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.Read More NWBO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NWBO Stock News HeadlinesJune 17 at 9:30 AM | prnewswire.comNorthwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual PropertyMay 25, 2024 | nasdaq.comNorthwest Biotherapeutics Inc (NWBO) Dividend HistoryJune 18, 2024 | Weiss Ratings (Ad)Reclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.March 21, 2024 | prnewswire.comNorthwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of DirectorsMarch 2, 2024 | ft.com‘Spoofing’ case might draw back curtain on high-speed trading firmsFebruary 29, 2024 | uk.finance.yahoo.comNorthwest Biotherapeutics, Inc. (NWBO)February 23, 2024 | benzinga.comNorthwest Biotherapeutics Stock (OTC:NWBO), Short Interest ReportFebruary 7, 2024 | finance.yahoo.comNorthwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory CertificationJune 18, 2024 | Weiss Ratings (Ad)Reclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.December 22, 2023 | msn.comNorthwest Biotherapeutics submits marketing application to UK MHRA for DCVax-LDecember 21, 2023 | finanznachrichten.deNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For GlioblastomaDecember 21, 2023 | finance.yahoo.comNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For GlioblastomaNovember 22, 2023 | finance.yahoo.comNorthwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization ApplicationOctober 31, 2023 | morningstar.comNorthwest Biotherapeutics Inc NWBOOctober 14, 2023 | msn.comNorthwest Bio: Another Small Filing DelayOctober 13, 2023 | seekingalpha.comNW Bio dips on announcing delay in submission of marketing application for DCVaxOctober 13, 2023 | marketwatch.comNorthwest Biotherapeutics Shares Slide on Application DelayOctober 13, 2023 | finance.yahoo.comNorthwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization ApplicationSeptember 12, 2023 | finance.yahoo.comNorthwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory BoardAugust 17, 2023 | msn.comNorthwest Bio: Is There Ever Going To Be A Right Time?August 6, 2023 | usnews.comNorthwest Missouri State UniversityAugust 4, 2023 | health.usnews.comNorthwest HospitalJuly 15, 2023 | thestreet.comWhy Northwest Bio Is Shunned by Savvy Health Care InvestorsJune 19, 2023 | pnj.comThree rounds of severe weather expected over the next 24 hours for Northwest FloridaJune 13, 2023 | health.usnews.comHCA Houston Healthcare NorthwestMay 27, 2023 | finance.yahoo.comNWBO - Northwest Biotherapeutics, Inc.May 9, 2023 | thestreet.comNorthwest Bio Warns FDA May Throw Out Phase III Brain Cancer StudySee More Headlines Receive NWBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:NWBO Previous SymbolNASDAQ:NWBO CUSIPN/A CIK1072379 Webwww.nwbio.com Phone(240) 497-9024Fax240-627-4121Employees25Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,600,000.00 Net Margins-5,258.91% Pretax Margin-5,258.91% Return on EquityN/A Return on Assets-241.52% Debt Debt-to-Equity RatioN/A Current Ratio0.08 Quick Ratio0.08 Sales & Book Value Annual Sales$1.93 million Price / Sales274.56 Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-7.20Miscellaneous Outstanding Shares1,226,620,000Free Float1,119,905,000Market Cap$529.90 million OptionableNot Optionable Beta-0.63 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMs. Linda F. Powers J.D. (Age 68)Chairperson, CEO, President, CFO & Chief Accounting Officer Comp: $1.1MDr. Alton L. Boynton Ph.D. (Age 79)Founder, Chief Scientific Officer, Secretary & Director Comp: $450kDr. Marnix L. Bosch M.B.A. (Age 65)Ph.D., Chief Technical Officer Comp: $597.5kMr. Leslie J. Goldman (Age 79)Senior VP & General Counsel Comp: $825kMr. David InnesVice President of Investor RelationsKey CompetitorsAmneal PharmaceuticalsNASDAQ:AMRXVera TherapeuticsNASDAQ:VERARocket PharmaceuticalsNASDAQ:RCKTMaravai LifeSciencesNASDAQ:MRVIAmphastar PharmaceuticalsNASDAQ:AMPHView All Competitors NWBO Stock Analysis - Frequently Asked Questions How have NWBO shares performed in 2024? Northwest Biotherapeutics' stock was trading at $0.7010 at the beginning of 2024. Since then, NWBO stock has decreased by 29.0% and is now trading at $0.4977. View the best growth stocks for 2024 here. How were Northwest Biotherapeutics' earnings last quarter? Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) issued its quarterly earnings data on Friday, May, 10th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The biotechnology company earned $0.28 million during the quarter. What other stocks do shareholders of Northwest Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), (ZLTQ) (ZLTQ), Avid Bioservices (CDMO), Idera Pharmaceuticals (IDRA), Amarin (AMRN), Inovio Pharmaceuticals (INO) and MEI Pharma (MEIP). How do I buy shares of Northwest Biotherapeutics? Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NWBO) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | Sponsoredwhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's alway...Prosper Trading Academy | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Northwest Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Northwest Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.